Theriva Biologics closes $7.5M public offering of common stock and warrants

Theriva Biologics, Inc.

Gross proceeds of ~$7.5M from offering of 6.8M shares (or pre-funded warrants) and common warrants at $1.10/unit.
Offering includes 1.99M shares, 4.83M pre-funded warrants, and 6.82M common warrants exercisable at $1.10 for 5 years.
Proceeds primarily for working capital, R&D, and manufacturing scale-up; no acquisition commitments.
Post-closing shares outstanding: 4,773,358 (excluding warrants).
A.G.P./Alliance Global Partners acted as placement agent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.